person · Reporting owner
AUBERTON-HERVE ANDRE-JACQUES
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionik Laboratories Corp.BNKL · Entity 112055 | Director | June 13, 2023 | June 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionik Laboratories Corp.
Report date June 13, 2023 · Filed June 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectShares held through Star SCI | 1,109,271 |
Reported balance
After 2023-06-13 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-06-13 · Conversion · Acquired 186,111 · Balance 1,109,271 F1: Effective as of June 13, 2023, approximately $310,185 of principal and accrued interest of a convertible promissory note issued to Star SCI, an affiliate of the reporting person, converted in accordance with its terms into 186,111 shares of the Issuer's common stock |
| Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2024-06-01 | IndirectThrough Star SCI | 1 |
Reported balance
After 2023-06-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-06-13 · Purchase · Acquired 1 · Balance 1 F2: The convertible promissory note (the "Note") will be convertible into common stock of the Issuer upon the following events on the following terms: (a) on June 1, 2024 without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to $0.60 per share; and (b) upon the consummation of the next equity or equity linked round of financing of the Issuer for cash proceeds (the "Qualified Financing"), without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to the lesser of (a) the issue price per share in the Qualified Financing and (b) $0.60 per share. |
| Common StockSEC Table I · non-derivative | IndirectShares held through 4A Consulting and Engineering | 10,693 |
Reported balance
Holding disclosure · report date 2023-06-13 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 10,693 |
| Common StockSEC Table I · non-derivative | Direct | 95,149 |
Reported balance
Holding disclosure · report date 2023-06-13 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 95,149 |
Filing footnotes · ownership attribution and instrument terms
F1: Effective as of June 13, 2023, approximately $310,185 of principal and accrued interest of a convertible promissory note issued to Star SCI, an affiliate of the reporting person, converted in accordance with its terms into 186,111 shares of the Issuer's common stock
F2: The convertible promissory note (the "Note") will be convertible into common stock of the Issuer upon the following events on the following terms: (a) on June 1, 2024 without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to $0.60 per share; and (b) upon the consummation of the next equity or equity linked round of financing of the Issuer for cash proceeds (the "Qualified Financing"), without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to the lesser of (a) the issue price per share in the Qualified Financing and (b) $0.60 per share.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MOBIX LABS, INC
Report date December 21, 2023 · Filed December 26, 2023
Section 16 reporting ended · disclosed 2023-12-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 342,917 |
Reported balance
After 2023-12-21 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-12-21 · Grant · Acquired 145,335 · Balance 342,917 F1: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc." F2: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor. F3: Includes an additional 197,582 shares of Class A Common Stock that may be deemed to be indirectly owned by the Reporting Person through his direct and indirect ownership interests in Sponsor, which shares are expected to be distributed to the Reporting Person over time. In addition, the Reporting Person holds private placement warrants, exercisable to purchase shares of Class A Common Stock of the Issuer at an exercise price of $11.50 per share, subject to certain adjustments, which he received in a pro rata distribution from the Sponsor on December 21, 2023. F4: The Sponsor is the record holder of the securities reported herein. The Reporting Person owns certain interests in the Sponsor and securities indirectly attributable to the Reporting Person are expected to be distributed to the Reporting Person over time. The Reporting Person disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee footnote | 540,966 |
Reported balance
After 2023-12-21 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-12-21 · Grant · Acquired 198,049 · Balance 540,966 F1: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc." F2: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor. F4: The Sponsor is the record holder of the securities reported herein. The Reporting Person owns certain interests in the Sponsor and securities indirectly attributable to the Reporting Person are expected to be distributed to the Reporting Person over time. The Reporting Person disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly. |
| Make-Whole Shares (right to acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 | IndirectSee footnote | 145,335 |
Reported balance
After 2023-12-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-12-21 · Grant · Acquired 145,335 · Balance 145,335 F5: Pursuant to the Subscription Agreement for the PIPE Investment, the Issuer has agreed to issue additional shares of Class A Common Stock if the volume weighted average price per share of Class A Common Stock during the 30-day period (the "Adjustment Period") commencing on the date that is 30 days after the date on which a resale Registration Statement relating to the PIPE Investment is declared effective (the "Adjustment Period VWAP") is less than $10.00 per share. In such case, the Sponsor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of PIPE Shares held by the Sponsor through the end of the Adjustment Period multiplied by (y) a fraction, (A) the numerator of which is $10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP (the "Make-Whole Shares"). In the event that the Adjustment Period VWAP is less than $7.00, the Adjustment Period VWAP will be deemed to be $7.00. F2: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor. F1: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc." F4: The Sponsor is the record holder of the securities reported herein. The Reporting Person owns certain interests in the Sponsor and securities indirectly attributable to the Reporting Person are expected to be distributed to the Reporting Person over time. The Reporting Person disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly. |
| Class A Common StockSEC Table I · non-derivative | Direct | 27,826 |
Reported balance
Holding disclosure · report date 2023-12-21 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 27,826 |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc."
F2: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor.
F3: Includes an additional 197,582 shares of Class A Common Stock that may be deemed to be indirectly owned by the Reporting Person through his direct and indirect ownership interests in Sponsor, which shares are expected to be distributed to the Reporting Person over time. In addition, the Reporting Person holds private placement warrants, exercisable to purchase shares of Class A Common Stock of the Issuer at an exercise price of $11.50 per share, subject to certain adjustments, which he received in a pro rata distribution from the Sponsor on December 21, 2023.
F4: The Sponsor is the record holder of the securities reported herein. The Reporting Person owns certain interests in the Sponsor and securities indirectly attributable to the Reporting Person are expected to be distributed to the Reporting Person over time. The Reporting Person disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
F5: Pursuant to the Subscription Agreement for the PIPE Investment, the Issuer has agreed to issue additional shares of Class A Common Stock if the volume weighted average price per share of Class A Common Stock during the 30-day period (the "Adjustment Period") commencing on the date that is 30 days after the date on which a resale Registration Statement relating to the PIPE Investment is declared effective (the "Adjustment Period VWAP") is less than $10.00 per share. In such case, the Sponsor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of PIPE Shares held by the Sponsor through the end of the Adjustment Period multiplied by (y) a fraction, (A) the numerator of which is $10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP (the "Make-Whole Shares"). In the event that the Adjustment Period VWAP is less than $7.00, the Adjustment Period VWAP will be deemed to be $7.00.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 21, 2023 Filed Dec 26, 2023 22:56 UTC | MOBIX LABS, INC MOBX · Entity 7651 | GrantMake-Whole Shares (right to acquire) · Derivative | 145,335 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001104659-23-129309 · tm2333669-16_4seq1.xml · derivative · entry 4 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 145,335 Underlying: Class A Common Stock · 145,335 shares Expires not disclosed F5 · kind: Pursuant to the Subscription Agreement for the PIPE Investment, the Issuer has agreed to issue additional shares of Class A Common Stock if the volume weighted average price per share of Class A Common Stock during the 30-day period (the "Adjustment Period") commencing on the date that is 30 days after the date on which a resale Registration Statement relating to the PIPE Investment is declared effective (the "Adjustment Period VWAP") is less than $10.00 per share. In such case, the Sponsor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of PIPE Shares held by the Sponsor through the end of the Adjustment Period multiplied by (y) a fraction, (A) the numerator of which is $10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP (the "Make-Whole Shares"). In the event that the Adjustment Period VWAP is less than $7.00, the Adjustment Period VWAP will be deemed to be $7.00. F2 · shares: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor. F1 · price: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc." F5 · price: Pursuant to the Subscription Agreement for the PIPE Investment, the Issuer has agreed to issue additional shares of Class A Common Stock if the volume weighted average price per share of Class A Common Stock during the 30-day period (the "Adjustment Period") commencing on the date that is 30 days after the date on which a resale Registration Statement relating to the PIPE Investment is declared effective (the "Adjustment Period VWAP") is less than $10.00 per share. In such case, the Sponsor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of PIPE Shares held by the Sponsor through the end of the Adjustment Period multiplied by (y) a fraction, (A) the numerator of which is $10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP (the "Make-Whole Shares"). In the event that the Adjustment Period VWAP is less than $7.00, the Adjustment Period VWAP will be deemed to be $7.00. F5 · derivative.exercise_date: Pursuant to the Subscription Agreement for the PIPE Investment, the Issuer has agreed to issue additional shares of Class A Common Stock if the volume weighted average price per share of Class A Common Stock during the 30-day period (the "Adjustment Period") commencing on the date that is 30 days after the date on which a resale Registration Statement relating to the PIPE Investment is declared effective (the "Adjustment Period VWAP") is less than $10.00 per share. In such case, the Sponsor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of PIPE Shares held by the Sponsor through the end of the Adjustment Period multiplied by (y) a fraction, (A) the numerator of which is $10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP (the "Make-Whole Shares"). In the event that the Adjustment Period VWAP is less than $7.00, the Adjustment Period VWAP will be deemed to be $7.00. F5 · derivative.expiration_date: Pursuant to the Subscription Agreement for the PIPE Investment, the Issuer has agreed to issue additional shares of Class A Common Stock if the volume weighted average price per share of Class A Common Stock during the 30-day period (the "Adjustment Period") commencing on the date that is 30 days after the date on which a resale Registration Statement relating to the PIPE Investment is declared effective (the "Adjustment Period VWAP") is less than $10.00 per share. In such case, the Sponsor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of PIPE Shares held by the Sponsor through the end of the Adjustment Period multiplied by (y) a fraction, (A) the numerator of which is $10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP (the "Make-Whole Shares"). In the event that the Adjustment Period VWAP is less than $7.00, the Adjustment Period VWAP will be deemed to be $7.00. F2 · derivative.underlying_shares: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor. F5 · derivative.underlying_shares: Pursuant to the Subscription Agreement for the PIPE Investment, the Issuer has agreed to issue additional shares of Class A Common Stock if the volume weighted average price per share of Class A Common Stock during the 30-day period (the "Adjustment Period") commencing on the date that is 30 days after the date on which a resale Registration Statement relating to the PIPE Investment is declared effective (the "Adjustment Period VWAP") is less than $10.00 per share. In such case, the Sponsor will be entitled to receive a number of shares of Class A Common Stock equal to the product of (x) the number of PIPE Shares held by the Sponsor through the end of the Adjustment Period multiplied by (y) a fraction, (A) the numerator of which is $10.00 minus the Adjustment Period VWAP and (B) the denominator of which is the Adjustment Period VWAP (the "Make-Whole Shares"). In the event that the Adjustment Period VWAP is less than $7.00, the Adjustment Period VWAP will be deemed to be $7.00. F2 · balance_after: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor. F4 · ownership.nature: The Sponsor is the record holder of the securities reported herein. The Reporting Person owns certain interests in the Sponsor and securities indirectly attributable to the Reporting Person are expected to be distributed to the Reporting Person over time. The Reporting Person disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 22:56 UTC | MOBIX LABS, INC MOBX · Entity 7651 | GrantClass A Common Stock | 198,049 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-129309 · tm2333669-16_4seq1.xml · nonDerivative · entry 2 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 540,966 F1 · kind: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc." F2 · shares: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor. F1 · price: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc." F4 · ownership.nature: The Sponsor is the record holder of the securities reported herein. The Reporting Person owns certain interests in the Sponsor and securities indirectly attributable to the Reporting Person are expected to be distributed to the Reporting Person over time. The Reporting Person disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Read SEC document |
| December 21, 2023 Filed Dec 26, 2023 22:56 UTC | MOBIX LABS, INC MOBX · Entity 7651 | GrantClass A Common Stock | 145,335 | $10.00 | $1,453,350.00 |
DisclosureSEC source: 0001104659-23-129309 · tm2333669-16_4seq1.xml · nonDerivative · entry 1 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 342,917 F1 · kind: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc." F2 · shares: Number of shares reported represents shares indirectly attributable to the Reporting Person through his ownership interests in Sponsor. F1 · price: Pursuant to a Subscription Agreement, Chavant Capital Partners LLC (the "Sponsor") purchased 199,737 shares of Class A Common Stock in connection with the closing (the "Closing") of Chavant Capital Acquisition Corp.'s initial business combination (the "Business Combination") with Mobix Labs, Inc. (the "Target"), on December 21, 2023 for aggregate consideration of $1,997,370, consisting of the forgiveness of certain indebtedness and certain expense reimbursement obligations owed by the Issuer to the Sponsor and its members (the "PIPE Investment" and such shares, the "PIPE Shares"). In connection with the entry into the Subscription Agreement, the Target issued the Sponsor a warrant to purchase 272,454 shares of stock of the Target, which was net exercised for 272,182 shares of common stock of the Target, which shares were automatically converted into shares of Class A Common Stock of the Issuer upon the Closing. In connection with the Closing, the Issuer was renamed "Mobix Labs, Inc." F3 · balance_after: Includes an additional 197,582 shares of Class A Common Stock that may be deemed to be indirectly owned by the Reporting Person through his direct and indirect ownership interests in Sponsor, which shares are expected to be distributed to the Reporting Person over time. In addition, the Reporting Person holds private placement warrants, exercisable to purchase shares of Class A Common Stock of the Issuer at an exercise price of $11.50 per share, subject to certain adjustments, which he received in a pro rata distribution from the Sponsor on December 21, 2023. F4 · ownership.nature: The Sponsor is the record holder of the securities reported herein. The Reporting Person owns certain interests in the Sponsor and securities indirectly attributable to the Reporting Person are expected to be distributed to the Reporting Person over time. The Reporting Person disclaims any beneficial ownership of the securities held by the Sponsor other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Read SEC document |
| June 13, 2023 Filed Jun 21, 2023 10:58 UTC | Bionik Laboratories Corp. BNKL · Entity 112055 | PurchaseConvertible Promissory Note · Derivative | 1 | $220,000.00 Strike: $0.60 | $220,000.00 |
DisclosureSEC source: 0001104659-23-073231 · tm2319148-4_4seq1.xml · derivative · entry 4 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Through Star SCI Disclosed balance after: 1 Underlying: Common Stock, par value $0.001 per share · 366,667 shares Expires 2024-06-01 F2 · derivative.exercise_price: The convertible promissory note (the "Note") will be convertible into common stock of the Issuer upon the following events on the following terms: (a) on June 1, 2024 without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to $0.60 per share; and (b) upon the consummation of the next equity or equity linked round of financing of the Issuer for cash proceeds (the "Qualified Financing"), without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to the lesser of (a) the issue price per share in the Qualified Financing and (b) $0.60 per share. F2 · derivative.exercise_date: The convertible promissory note (the "Note") will be convertible into common stock of the Issuer upon the following events on the following terms: (a) on June 1, 2024 without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to $0.60 per share; and (b) upon the consummation of the next equity or equity linked round of financing of the Issuer for cash proceeds (the "Qualified Financing"), without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to the lesser of (a) the issue price per share in the Qualified Financing and (b) $0.60 per share. F2 · derivative.expiration_date: The convertible promissory note (the "Note") will be convertible into common stock of the Issuer upon the following events on the following terms: (a) on June 1, 2024 without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to $0.60 per share; and (b) upon the consummation of the next equity or equity linked round of financing of the Issuer for cash proceeds (the "Qualified Financing"), without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to the lesser of (a) the issue price per share in the Qualified Financing and (b) $0.60 per share. F2 · derivative.underlying_shares: The convertible promissory note (the "Note") will be convertible into common stock of the Issuer upon the following events on the following terms: (a) on June 1, 2024 without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to $0.60 per share; and (b) upon the consummation of the next equity or equity linked round of financing of the Issuer for cash proceeds (the "Qualified Financing"), without any action on the part of the reporting person, the outstanding principal and accrued and unpaid interest under the Note will be converted into shares of common stock at a conversion price equal to the lesser of (a) the issue price per share in the Qualified Financing and (b) $0.60 per share. Read SEC document |
| June 13, 2023 Filed Jun 21, 2023 10:58 UTC | Bionik Laboratories Corp. BNKL · Entity 112055 | ConversionCommon Stock | 186,111 | $0.60 | $111,666.60 |
DisclosureSEC source: 0001104659-23-073231 · tm2319148-4_4seq1.xml · nonDerivative · entry 1 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held through Star SCI Disclosed balance after: 1,109,271 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Effective as of June 13, 2023, approximately $310,185 of principal and accrued interest of a convertible promissory note issued to Star SCI, an affiliate of the reporting person, converted in accordance with its terms into 186,111 shares of the Issuer's common stock Read SEC document |
| June 09, 2023 Filed Jun 21, 2023 10:55 UTC | Bionik Laboratories Corp. BNKL · Entity 112055 | PurchaseCommon Stock | 650,000 | $0.60 | $390,000.00 |
DisclosureSEC source: 0001104659-23-073228 · tm2319148-5_4seq1.xml · nonDerivative · entry 1 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Shares held through Star SCI Disclosed balance after: 923,160 F1 · price: The reporting person acquired the shares of common stock in lieu of cash payment of an aggregate of $390,000 in accrued and unpaid fees relating to reporting person's services as Chairman of the Board of the Issuer. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 16:38 UTC | MOBIX LABS, INC CLAY · Entity 7651 | Disposition to issuerOrdinary Shares | 4,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-027820 · tm227631-1_4seq1.xml · nonDerivative · entry 1 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,826 F1 · shares: The ordinary shares are described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-257459) (the "Registration Statement") and have no expiration date. On February 24, 2022, the Reporting Person transferred 4,174 ordinary shares to Chavant Capital Partners LLC, the sponsor of the Issuer, for no consideration. F1 · price: The ordinary shares are described under the heading "Description of Securities" in the Issuer's Registration Statement on Form S-1 (File No. 333-257459) (the "Registration Statement") and have no expiration date. On February 24, 2022, the Reporting Person transferred 4,174 ordinary shares to Chavant Capital Partners LLC, the sponsor of the Issuer, for no consideration. Read SEC document |
| July 15, 2021 Filed Jun 21, 2022 17:49 UTC | Bionik Laboratories Corp. BNKL · Entity 112055 | Exercise / conversionStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001104659-22-073086 · tm2218715-2_4seq1.xml · derivative · entry 5 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 per share · 7,500 shares Expires 2026-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Payment of exercise price was satisfied through the satisfaction of an Issuer promissory note held by the reporting person. F2 · derivative.exercise_date: The options vest 2,500 on May 31, 2019, 2,500 on November 30, 2019 and 2,500 on May 31, 2020. Read SEC document |
| July 15, 2021 Filed Jun 21, 2022 17:49 UTC | Bionik Laboratories Corp. BNKL · Entity 112055 | Exercise / conversionStock Option (right to buy) · Derivative | 51,878 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001104659-22-073086 · tm2218715-2_4seq1.xml · derivative · entry 4 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,881 Underlying: Common Stock, par value $0.001 per share · 51,878 shares Expires 2026-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Payment of exercise price was satisfied through the satisfaction of an Issuer promissory note held by the reporting person. Read SEC document |
| July 15, 2021 Filed Jun 21, 2022 17:49 UTC | Bionik Laboratories Corp. BNKL · Entity 112055 | Exercise / conversionCommon Stock, par value $0.001 per share | 7,500 | $3.16 | $23,700.00 |
DisclosureSEC source: 0001104659-22-073086 · tm2218715-2_4seq1.xml · nonDerivative · entry 2 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held through Star SCI or 4A Consulting and Engineering Disclosed balance after: 283,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Payment of exercise price was satisfied through the satisfaction of an Issuer promissory note held by the reporting person. Read SEC document |
| July 15, 2021 Filed Jun 21, 2022 17:49 UTC | Bionik Laboratories Corp. BNKL · Entity 112055 | Exercise / conversionCommon Stock, par value $0.001 per share | 51,878 | $3.60 | $186,501.41 |
DisclosureSEC source: 0001104659-22-073086 · tm2218715-2_4seq1.xml · nonDerivative · entry 1 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held through Star SCI or 4A Consulting and Engineering Disclosed balance after: 276,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Payment of exercise price was satisfied through the satisfaction of an Issuer promissory note held by the reporting person. Read SEC document |
| March 26, 2021 Filed Apr 1, 2021 12:22 UTC | Bionik Laboratories Corp. BNKL · Entity 112055 | PurchaseCommon Stock, par value $0.001 per share | 95,149 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-045413 · tm2111532-2_4seq1.xml · nonDerivative · entry 1 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,149 F1 · price: The reporting person acquired the shares of common stock in lieu of cash payment for an aggregate of $255,000 in accrued and unpaid fees relating to reporting person's services as a director of the Issuer. Read SEC document |
| July 26, 2019 Filed Aug 8, 2019 15:50 UTC | Bionik Laboratories Corp. BNKL · Entity 112055 | GrantEmployee Stock Option (right to buy) · Derivative | 115,759 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001144204-19-038541 · tv526242_4.xml · derivative · entry 1 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,759 Underlying: Common Stock, par value $0.001 · 115,759 shares Expires 2026-07-26 F1 · derivative.exercise_date: The option shall be fully vested on the occurrence of any of the following conditions: (a) A Change of Control (as defined in the Company's 2014 Equity Incentive Plan) or (b) upon the Reporting Person not being Chairman of the Board of the Issuer for any reason. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 15:57 UTC | Bionik Laboratories Corp. BNKL · Entity 112055 | GrantEmployee Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001144204-19-029709 · tv523059_4.xml · derivative · entry 1 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock, par value $0.001 · 7,500 shares Expires 2026-05-31 F1 · derivative.exercise_date: The options vest 2,500 on May 31, 2019, 2,500 on November 30, 2019 and 2,500 on May 31, 2020. Read SEC document |
| March 28, 2019 Filed Apr 9, 2019 18:42 UTC | Bionik Laboratories Corp. BNKL · Entity 112055 | ConversionCommon Stock | 81,492 | $3.89 | $316,800.15 |
DisclosureSEC source: 0001144204-19-018936 · tv518554_4.xml · nonDerivative · entry 1 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held through Star SCI and 4A Consulting & Engineering Disclosed balance after: 224,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Effective as of March 28, 2019, an aggregate amount of $316,800 of principal and accrued interest in convertible promissory notes issued to Star SCI (the "Notes") converted in accordance with their terms into 81,492 shares of the Issuer's common stock. F2 · shares: The conversion price of the Notes was calculated using the VWAP (as defined in the Notes) average of the last 30 days before March 28, 2019. F2 · price: The conversion price of the Notes was calculated using the VWAP (as defined in the Notes) average of the last 30 days before March 28, 2019. Read SEC document |
| July 24, 2018 Filed Jul 26, 2018 13:55 UTC | Bionik Laboratories Corp. BNKL · Entity 112055 | ConversionCommon Stock | 6,688,480 | $0.05 | $343,119.02 |
DisclosureSEC source: 0001144204-18-040074 · tv499375_4.xml · nonDerivative · entry 1 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held through Star SCI and 4A Consulting & Engineering Disclosed balance after: 21,447,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Effective as of July 20, 2018, an aggregate amount of $308,807 in convertible promissory notes issued to Star SCI (the "Notes") converted in accordance with their terms into 6,688,480 shares of the Issuer's common stock. For purposes of the filing of this Form 4, the transaction date is deemed to be July 24, 2018, as that was the date that the Issuer preliminarily determined the number of shares of common stock that the Notes were convertible into in accordance with the terms of the Notes. F2 · shares: The conversion price of the Notes was calculated using the VWAP (as defined in the Notes) average of the last 30 days before July 20, 2018. As of the date hereof, the Issuer has not definitively determined the conversion price. In the event that the Issuer definitively determines that the conversion price was lower than $0.0513, the Reporting Person will file an amendment to this Form 4 to reflect the correct conversion price, number of shares acquired upon conversion, and the amount of securities beneficially owned following the reported transaction. F2 · price: The conversion price of the Notes was calculated using the VWAP (as defined in the Notes) average of the last 30 days before July 20, 2018. As of the date hereof, the Issuer has not definitively determined the conversion price. In the event that the Issuer definitively determines that the conversion price was lower than $0.0513, the Reporting Person will file an amendment to this Form 4 to reflect the correct conversion price, number of shares acquired upon conversion, and the amount of securities beneficially owned following the reported transaction. F2 · balance_after: The conversion price of the Notes was calculated using the VWAP (as defined in the Notes) average of the last 30 days before July 20, 2018. As of the date hereof, the Issuer has not definitively determined the conversion price. In the event that the Issuer definitively determines that the conversion price was lower than $0.0513, the Reporting Person will file an amendment to this Form 4 to reflect the correct conversion price, number of shares acquired upon conversion, and the amount of securities beneficially owned following the reported transaction. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 14:39 UTC | Bionik Laboratories Corp. BNKL · Entity 112055 | ConversionCommon Stock | 1,039,115 | $0.06 | $64,944.69 |
DisclosureSEC source: 0001144204-18-034393 · tv496575_4.xml · nonDerivative · entry 2 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held through 4A Consulting and Engineering Disclosed balance after: 14,758,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: As previously disclosed by the reporting person on a Form 4, filed with the Securities and Exchange Commission on April 3, 2018, as of March 31, 2018, the Issuer became obligated to issue 1,039,115 shares of common stock (the "4A Shares") to 4A Consulting and Engineering, an affiliate of the reporting person, as a result of the conversion of certain outstanding convertible promissory notes in accordance with their terms. The reporting person is filing this Form 4 to disclose that the Issuer issued the 4A Shares as of June 13, 2018. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 14:39 UTC | Bionik Laboratories Corp. BNKL · Entity 112055 | ConversionCommon Stock | 1,040,152 | $0.06 | $65,009.50 |
DisclosureSEC source: 0001144204-18-034393 · tv496575_4.xml · nonDerivative · entry 1 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held through Star SCI Disclosed balance after: 14,758,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: As previously disclosed by the reporting person on a Form 4, filed with the Securities and Exchange Commission on April 3, 2018, as of March 31, 2018, the Issuer became obligated to issue 1,010,152 shares of common stock (the "Star Shares") to Star SCI, an affiliate of the reporting person, as a result of the conversion of certain outstanding convertible promissory notes in accordance with their terms. The reporting person is filing this Form 4 to disclose that the Issuer issued the Star Shares as of June 13, 2018. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 19:26 UTC | Bionik Laboratories Corp. BNKL · Entity 112055 | ConversionCommon Stock | 564,726 | $0.06 | $35,295.38 |
DisclosureSEC source: 0001144204-18-019057 · tv490253_4.xml · nonDerivative · entry 2 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held through 4A Consulting and Engineering Disclosed balance after: 12,679,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: On March 31, 2018, an aggregate amount of $100,200 in convertible promissory notes converted in accordance with their terms into (i) 564,726 shares of the Issuer's common stock, and (ii) 1,039,115 shares of the Issuer's common stock (the "Pending Shares") that will be issued upon the earlier of (i) a reverse stock split of the Issuers's common stock that allows for the issuance of the Pending Shares without violating the authorized share number of the Issuer and (ii) an increase in the Issuer's authorized shares of common stock. The amounts set forth in this Form 4 do not reflect the issuance of the Pending Shares, and the Reporting Person will either amend this Form 4 or file a new Form 4 reflecting the issuance. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 19:26 UTC | Bionik Laboratories Corp. BNKL · Entity 112055 | ConversionCommon Stock | 12,114,710 | $0.06 | $757,169.38 |
DisclosureSEC source: 0001144204-18-019057 · tv490253_4.xml · nonDerivative · entry 1 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held through Star SCI Disclosed balance after: 12,679,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On March 31, 2018, an aggregate amount of $821,850 in convertible promissory notes converted in accordance with their terms into (i) 12,114,710 shares of the Issuer's common stock, and (ii) 1,040,152 shares of the Issuer's common stock (the "Pending Shares") that will be issued upon the earlier of (i) a reverse stock split of the Issuers's common stock that allows for the issuance of the Pending Shares without violating the authorized share number of the Issuer and (ii) an increase in the Issuer's authorized shares of common stock. The amounts set forth in this Form 4 do not reflect the issuance of the Pending Shares, and the Reporting Person will either amend this Form 4 or file a new Form 4 reflecting the issuance. Read SEC document |
| August 14, 2017 Filed Apr 3, 2018 19:26 UTC | Bionik Laboratories Corp. BNKL · Entity 112055 | GrantWarrant · Derivative | 1,600,640 | $0.00 Strike: $0.06 | $0.00 |
DisclosureSEC source: 0001144204-18-019057 · tv490253_4.xml · derivative · entry 3 AUBERTON-HERVE ANDRE-JACQUES · CIK 0001730329 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Warrants held through held through Star SCI Disclosed balance after: 1,600,640 Underlying: Common Stock · 1,600,640 shares Expires 2022-08-14 F3 · date: As of the transaction date, the number of shares of common stock underlying warrants and the exercise price were not yet determinable. Such number of shares and exercise price were each determined on March 31, 2018. F3 · derivative.exercise_date: As of the transaction date, the number of shares of common stock underlying warrants and the exercise price were not yet determinable. Such number of shares and exercise price were each determined on March 31, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.